High use of short-acting β(2)-agonists in COPD is associated with an increased risk of exacerbations and mortality

BACKGROUND: Short-acting β(2)-agonist (SABA) overuse has been associated with an increased risk of exacerbations in asthma; however, less is known about SABA use in COPD. Our aim was to describe SABA use and investigate potential associations between high SABA use and the risk of future exacerbation...

Descripción completa

Detalles Bibliográficos
Autores principales: Janson, Christer, Wiklund, Fredrik, Telg, Gunilla, Stratelis, Georgios, Sandelowsky, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277875/
https://www.ncbi.nlm.nih.gov/pubmed/37342089
http://dx.doi.org/10.1183/23120541.00722-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277875/
https://www.ncbi.nlm.nih.gov/pubmed/37342089
http://dx.doi.org/10.1183/23120541.00722-2022

Ejemplares similares